Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Ionis Pharmaceuticals, Inc. (844) 748-5844
IonisHORIZONStudy@clinicaltrialmedia.com


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
Back

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)

Recruiting

Open to: ALL

Age: 40.0 - 70.0

Southampton Salford London Oxford

Medical Conditions

Multiple System Atrophy

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary objectives are to evaluate the safety and tolerability of multiple doses of ION464 administered via intrathecal (IT) injection (Part 1) and to evaluate the long-term safety and tolerability of ION464 (Part 2) in participants with multiple system atrophy (MSA).

The secondary objectives are to evaluate the pharmacodynamic (PD) effect of ION464 on the level of a potential biomarker of target engagement (Parts 1 and 2) and to evaluate the pharmacokinetic (PK) profile of ION464 in serum (Part 1).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2022 Sep 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : ION464 will be administered by IT injection.

Intervention Arm Group : Part 1: ION464;Part 2: ION464;

Intervention Type : DRUG
Intervention Description : ION464-matching placebo will be administered by IT injection.

Intervention Arm Group : Part 1: Placebo;Part 2: Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Southampton General Hospital
    Southampton
    SO16 6YD
  • Salford Royal Hospital
    Salford
    M6 8HD
  • Institute of Neurology & The National Hospital for Neurology and Neurosurgery
    London
    England
    WC1N 3BG
  • The John Radcliffe Hospital
    Oxford
    England
    OX3 9DU

Ionis Pharmaceuticals, Inc. (844) 748-5844
IonisHORIZONStudy@clinicaltrialmedia.com



The study is sponsored by Ionis Pharmaceuticals, Inc.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04165486
Last updated 24 April 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top